Q3 2024 AngioDynamics Inc Earnings Call

Operator: Ladies and gentlemen, thank you for standing by. AngioDynamics will begin in just a few moments. Once again, we thank you for standing by. Please continue to hold.

Ladies and gentlemen, thank you for standing by Angio dynamics will begin in just a few moments.

Once again, we thank you first to anybody please continue to hold and Urodynamics will begin shortly.

Music: Please see the complete disclaimer at https://sites.google.com.au

[music].

Operator: Good morning, and welcome to the AngioDynamics Fiscal Year 2024 Third Quarter Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad.

Operator: As a reminder, this conference call is being recorded. The news release detailing AngioDynamics' fiscal 2024 third quarter results crossed the wire earlier this morning and is available on the company's website. This conference call is also being broadcast live over the Internet in the Investors section of the company's website at www.angiodynamics.com, and a webcast replay of the call will be available at the same site approximately one hour after the end of today's call.

None: Good morning, and welcome to the Android dynamics fiscal year 2024 third quarter earnings call.

None: At this time all participants are in a listen only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance. During the conference. Please press star zero on your telephone keypad.

Operator: Before we begin, I would like to caution listeners that during the course of this conference call, the company will make projections or forward-looking statements regarding future events, including statements about expected revenue, adjusted earnings, and gross margins for fiscal year 2024, as well as trends that may continue. Management encourages you to review the company's past and future filings with the SEC, including, without limitation, the company's Forms 10-Q and 10-K, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statement. The company will also discuss certain non-GAAP and pro-forma financial measures during this call. Management uses these measures to establish operational goals and review operational performance and believes that these measures may assist investors in analyzing the underlying trends in the company's business over time.

None: As a reminder, this conference call is being recorded.

None: The news release detailing and your dynamics fiscal 2024 third quarter results crossed the wire earlier. This morning and is available on the company's website.

None: This conference call is also being broadcast live over the Internet at the investors section of the company's website at Www Dot Angio dynamics Dot com and the webcast replay of the call will be available at the same site approximately one hour after the end of today's call.

None: Before we begin I would like to caution listeners that during the course of this conference call. The company will make projections or forward looking statements regarding future events, including statements about expected revenue adjusted earnings and gross margins for fiscal year 2024, as well as trends that may continue Matt.

Operator: Investors should consider these non-GAAP and pro-FOMA measures in addition to, not as a substitute for, or as superior to, financial reporting measures prepared in accordance with GAAP. A slide package offering insight into the company's financial results is also available in the Investor section of the company's website under Events and Presentations. This presentation should be read in conjunction with the press release discussing the company's operating results and financial performance discussed during this morning's conference call. I'd now like to turn the call over to Jim Clemmer, AngioDynamics President and Chief Executive Officer. Mr. Clemmer?

None: <unk> encourages you to review the company's <unk>.

Past and future filings with the SEC, including without limitation, the company's forms 10-Q, and 10-K, which identify specific factors that may cause the actual results or events to differ materially from those described in the forward looking statements.

James C. Clemmer: Thank you. Good morning, everyone, and thank you for joining us for AngioDynamics' Fiscal 2024 Third Quarter Earnings Call. Joining me on today's call is Steve Trowbridge, AngioDynamics Executive Vice President and Chief Financial Officer, who will provide a detailed analysis of our third quarter financial performance. Unless otherwise noted, all financial metrics and growth rates provided during the call today with respect to our results will be on a pro forma basis, which excludes the impact of our divested dialysis, biocentry, and other measures.

The company will also discuss certain non-GAAP and pro forma financial measures during this call.

None: Management uses these measures to establish operational goals and review operational performance and.

None: And believes that these measures may assist investors in analyzing the underlying trends in the company's business overtime.

None: Investors should consider these non-GAAP and pro farm out measures in addition to not as a substitute for them.

None: Or as superior to financial reporting measures prepared in accordance with GAAP.

James C. Clemmer: pick

James C. Clemmer: and Midline Business, and our discontinued radiofrequency and Syntrax support catheter product. We are very pleased with the solid performer revenue growth that we saw during our third quarter.

None: A slide package offering insight into the company's financial results is also available on the investors section of the company's website under events and presentations.

James C. Clemmer: We executed on a number of significant strategic milestones during and after Q3, including securing an expanded indication and reaching a settlement agreement with BD Bars. Additionally, we announced another significant step in the optimization of our portfolio, with the divestiture of our pick and midline product portfolio. This divestiture, combined with the ongoing shift of manufacturing out of our upstate New York manufacturing facility and the divestiture of our dialysis and biocentry businesses to Merit Medical at the beginning of this fiscal year, positioned us to drive further growth from our key medtech platforms while also expanding margins and driving towards profitability. We will cover this in more detail shortly.

None: This presentation should be read in conjunction with the press release discussing the company's operating results and financial performance. During this morning's conference call.

None: I'd now like to turn the call over to Jim Clemmer, and Youre, Dynamics', President and Chief Executive Officer, Mr. Clemmer.

James C. Clemmer: Thank you.

James C. Clemmer: Good morning, everyone and thank you for joining us for Angel dynamics fiscal 'twenty 'twenty four third quarter earnings call.

James C. Clemmer: Joining me on today's call is Steve Trowbridge, Andrew dynamics, Executive Vice President and Chief Financial Officer.

James C. Clemmer: But now, turning to our third quarter results, our third quarter of fiscal 24 saw a return to double-digit year-over-year growth in our MedTech segment and solid mid-single-digit growth from our med device sector. We ended the third quarter with revenue of $66 million, representing growth of approximately 8% year-over-year, with growth of nearly 13% from our MedTech segment and 5% from our med device segment. Growth in the medtech segment was driven by Arion, which grew nearly 15% year-over-year, and NanoKnife, which grew approximately 47% during the third quarter, with sales of probes increasing approximately 20%. Our mechanical thrombectomy business, which includes AngioVac and AlphaVac, declined roughly 12% year-over-year, while AngioVac stabilizes, as we discussed last quarter. AlphaVac sales slowed due to a winding down at many of our sites as we completed enrollment in the Apex PE trial.

James C. Clemmer: I will provide a detailed analysis of our third quarter financial performance.

Stephen A. Trowbridge: Unless otherwise noted all financial metrics and growth rates provided during the call today with respect to our results will be on a pro forma basis, which excludes the impact of our divested dialysis biosensors.

Stephen A. Trowbridge: And Midland businesses.

Stephen A. Trowbridge: And our discontinued radio frequency and St tracks support catheter products.

Stephen A. Trowbridge: We are very pleased with the solid pro forma revenue graph that we saw during our third quarter, we executed on a number of significant strategic milestones during and after Q3, including securing an expanded indication Andrey.

James C. Clemmer: We expect a continued softness in Alpha Vaccin sales between the completion of the trial and FDA approval of the PE indication. We are pleased to announce today that we've received FDA clearance for the use of AlphaVac to treat pulmonary embolism. This approval came in ahead of our expectations, and I'm proud of the strong submission that our team put together and the compelling data generated by our APEX trial. This expanded indication is a significant piece of the long-term strategy that we laid out for you in July of 2021. This validation validates the unique design elements of our product and the significant benefit it provides to physicians and patients.

Stephen A. Trowbridge: And reaching a settlement agreement with BD Bard.

Stephen A. Trowbridge: Additionally, we announced another significant step in the optimization of our portfolio with the divestiture of our pitch and midline product portfolios.

Stephen A. Trowbridge: This divestiture combined with the ongoing shift of manufacturing out of our upstate New York manufacturing facilities.

Stephen A. Trowbridge: And the divestiture of our dialysis and buyer century businesses to merit medical that can be getting of this fiscal year.

Stephen A. Trowbridge: Positioning us to drive further growth from our key med tech platforms, while also expanding margins and driving towards profitability.

Stephen A. Trowbridge: We will cover this in more detail shortly.

Stephen A. Trowbridge: But now turning to our third quarter results.

James C. Clemmer: This approval opened up another large, fast-growing market for us, and we are excited to put AlphaVac in more physicians' hands. The results of our APEX trial exceeded our expectations, comfortably hitting our targeted endpoints and comparing favorably with other catheter-based PE treatment trials, given the unique design elements of our device. Specifically, the one-to-one torque maneuverability and the expandable funnel.

Stephen A. Trowbridge: Our third quarter of fiscal 'twenty four saw a return to double digit year over year growth in our med Tech segment and solid mid single digit growth from our med device segment.

Stephen A. Trowbridge: We ended the third quarter with revenue of $66 million representing growth of approximately 8% year over year with growth of nearly 13% from our med Tech segment.

Stephen A. Trowbridge: 5% Med device segment.

James C. Clemmer: Physicians were able to remove significantly more clot burden and complete the procedure in less time than has been reported in other PE trials. We look forward to more details being announced in publications over the coming months. This business will play an important role as we execute on our growth strategy. We expect to initiate a limited launch release during the end of our fiscal Q4, with a full launch scheduled during our Q1 of FY25. Additional Near-Term Catalyst, expected MDR approval of AlphaVac for treatment of PE in European and other markets, which we expect by the end of June. During the third quarter, we launched the Arion XL radial catheter, and this product is intended to give physicians another access point to treat peripheral artery disease. Many physicians like the radial approach, as they can perform more procedures per day, and patient follow-up is faster and generally has fewer potential complications.

Stephen A. Trowbridge: Growth in the Med Tech segment was driven by our yacht, which grew nearly 15% year over year and nano knife, which grew approximately 47% during the third quarter with sales of pros increasing approximately 20%.

Stephen A. Trowbridge: Our mechanical thrombectomy business, which includes angio vac and alphabet declined roughly 12% year over year.

Stephen A. Trowbridge: While angio Vac stabilized as we discussed last quarter.

Alpha backed sales slowed due to a wind down at many of our sites as we completed enrollment in the apex P E trial.

Stephen A. Trowbridge: We expect a continued softness in alpha back sales between the completion of the trial and the FDA approval of the P E indication.

Stephen A. Trowbridge: We are pleased to announce today that we've received our clearance from the FDA for.

Stephen A. Trowbridge: For the use of alphabet to treat pulmonary embolism.

Stephen A. Trowbridge: This approval came in ahead of our expectations and I'm proud of the strong submission that our team put together.

James C. Clemmer: This is another reason why potential customers will consider Arion for use in their cath labs or their OBLs. Currently, we expect to receive CE Mark for Ariane by the end of June, allowing us to expand promotion beyond the U.S. and into the EU market. Turning to our NanoKnife business, we continue to see increased interest in the usage of NanoKnife by Patients and Caregivers Seeking Options to Treat Intermediate We look forward to completing the 12-month patient follow-up in July for our preserve study, and then we will submit our data to the FDA, and we are currently expecting clearance, by the end of calendar 2024, growth of approximately 5% in our med device segment, primarily driven by our EVLT and our angiographic catheter product, 22% and 11%, respectively.

Stephen A. Trowbridge: And the compelling data generated by our apex trial.

Stephen A. Trowbridge: This expanded indication is a significant piece of the long term strategy that we laid out for you in July of 2021.

It validates the unique design elements of our product and a significant benefit it provides to physicians and patients.

Stephen A. Trowbridge: This approval open up another large fast growing market for us and we are excited to put alphabet and more physicians hands.

Stephen A. Trowbridge: The results of our apex trial exceeded our expectations.

Stephen A. Trowbridge: Comfortably hitting our targeted endpoints and comparing favorably with other catheter based P E treatment trials.

Stephen A. Trowbridge: Given the unique design elements of our device specifically, the one to one truck maneuverability and the expandable funnel.

James C. Clemmer: In the third quarter of FY24, our international business grew approximately 21% year-over-year, including approximately 53% growth from MedTech and 7% growth for MedDevice. We also hosted our fifth International Clinical Life Symposium.

Stephen A. Trowbridge: Physicians were able to remove significantly more clot burden.

Stephen A. Trowbridge: And complete the procedure and less time that has been reported and other P E trials.

Stephen A. Trowbridge: We look forward to more specifics being announced and publications over the coming months.

James C. Clemmer: These symposiums continue to drive increased interest and our MedTech Prize, and we have generated a meaningful pipeline of global physicians who are excited to utilize our products and care for their patients. Now turning to our portfolio optimization that I mentioned earlier. February 15th.

Stephen A. Trowbridge: This business will play an important role as we execute on our growth strategy.

Stephen A. Trowbridge: We expect to initiate a limited launch release during the end of our fiscal Q4 with a full launch scheduled during our Q1 of FY 'twenty five.

Stephen A. Trowbridge: Additional near term catalysts include expected M. D. R approval of alphabet for treatment of P E and European and other markets, which we expect by the end of June.

James C. Clemmer: We've sold our pick in midline portfolios and Spectrum Vascular for a total consideration of up to $45 million, with roughly $30 million received in our Q3. Additionally, we discontinued sales of our Uniblade and Starburst RF products, as well as our Syntrax support capital. These were older products that were not core to our growth strategy and would have cost us to transition them to our new outsourced model. In total, these divested and discontinued products contributed approximately $50 million in sales in FY23. We are much happier with where our portfolio sits today, with a higher-growth medtech business that is the foundation of our future growth and profitability, along with a less complex med device segment that can help support our investment and OrganicGrow, the transition of our manufacturing to a fully outsourced model, which we announced on our last call.

Stephen A. Trowbridge: During the third quarter, we launched the Oregon, XL radio catheter and this product is intended to give physicians another access point to treat peripheral artery disease.

Stephen A. Trowbridge: Many physicians, who like the radial approach.

They can perform more procedures per day and the patient follow up is faster and generally has fewer potential complications.

Stephen A. Trowbridge: This is another reason why potential customers will consider Oregon for use in their cath labs or their Ob ALS.

Stephen A. Trowbridge: We currently expect to receive CE Mark for our yacht by the end of June.

Stephen A. Trowbridge: Allowing us to expand promotion beyond the U S and into the EU markets.

Stephen A. Trowbridge: Turning to our nano life business, we continued to see increased interest in the usage of nano knife for patients and caregivers seeking options to treat intermediate risk prostate cancer.

James C. Clemmer: Now well underway, and OnTrack to generate approximately $15 million in annualized savings, starting in FY26, being fully realized in FY27. Looking at the combined divestitures to Spectrum and Merit this year, we received approximately two times the sales for the combined assets, and we were able to pay down all of our outstanding debt and strengthen our balance sheet significantly. Finally, as Steve will discuss in more detail, we reached a settlement on the more than a decade of IP litigation with B.B. Barr, for providing us with clarity and certainty in allowing us to focus on our strategic transformation. With that, I'll turn the call over to Steve Trowbridge, our Executive Vice President and Chief Financial Officer, to review the quarter in more detail.

Stephen A. Trowbridge: We look forward to completing the 12 months of patient follow up in July for a preserve study.

Stephen A. Trowbridge: And then we will submit our data to the F D. A.

Stephen A. Trowbridge: And we are currently expecting clearance by the end of calendar 2024.

Growth of approximately 5% and our med device segment was primarily driven by our E V. L T and our angiographic catheter products, which grew 22% and 11% respectively.

Stephen A. Trowbridge: In the third quarter of FY 'twenty for our international business grew approximately 21% year over year.

Stephen A. Trowbridge: Excluding approximately 53% growth from med tech and 7% growth for med device.

Stephen A. Trowbridge: We also hosted our fifth international clinical life Symposium.

Stephen A. Trowbridge: Thanks, Jim. Good morning, everybody. Before I begin, I'd like to direct everyone to the presentation on our Investor Relations website summarizing the key items from our quarterly results. As Jim mentioned, unless otherwise noted, all metrics and growth rates mentioned during today's call are on a pro forma basis and exclude the results of the dialysis and biocentric businesses that we divested last June, the PIC and Midline products that we divested last month, and the radiofrequency and Syntrex support Our revenue for the third quarter of FY24 increased 8% year-over-year to $66 million, driven by growth in both our MedTech and MedDevice platforms. MedTech revenue was $25.7 million, a 12.6% year-over-year increase, while MedDevice revenue was $40.3 million, growing 5.2% compared to the third quarter of FY23.

Stephen A. Trowbridge: These symposiums continue to drive increased interest in our med tech products.

Stephen A. Trowbridge: We have generated a meaningful pipeline of global physicians, who are excited to utilize our products and caring for their patients.

Stephen A. Trowbridge: Now turning to our portfolio optimization that I mentioned earlier.

Stephen A. Trowbridge: On February 15th we sold our pitch and midline portfolios the spectrum vascular.

Stephen A. Trowbridge: For a total consideration of up to $45 million with roughly $30 million received in our Q3.

Stephen A. Trowbridge: Additionally, we discontinued sales of our unit Blake and Starbursts RF products.

Stephen A. Trowbridge: As well as our central support catheter as these were older products that are not core to our growth strategy would have cost us to transition them to our new outsourced model.

Stephen A. Trowbridge: In total.

Stephen A. Trowbridge: These divested and discontinued products contributed approximately 50 million of sales in FY2023.

Stephen A. Trowbridge: We are much happier with where our portfolio sits today with the higher growth Med Tech business. It is the foundation of our future growth and profitability.

Stephen A. Trowbridge: Year-to-date, our overall revenue is up 6.5% year-over-year, with our med tech segment up 9.6% and our med device segment up 4.6%. We were pleased with the return to growth that we saw across both our medtech and meddevice businesses in the third quarter, which we had expected and is reflective of the strength of our portfolio. For the third fiscal quarter, on a pro forma basis, our MedTech platforms comprised 38.9% of our total revenue, compared to 37.3% of total revenue a year ago. For the nine months ended February 29th, 2024, our MedTech segment comprised 38.4% of our total world revenue base versus 37.3% as of one year ago. Our ARION platform contributed $11.8 million in revenue during the third quarter, growing 14.7% compared to last year. Year-to-date, our Ariane platform is up 17.4% year-over-year.

Stephen A. Trowbridge: Along with a less complex med device segment that can help support our investments in organic growth.

Stephen A. Trowbridge: The transition of our manufacturing to a fully outsourced model, which we announced on our last call.

Stephen A. Trowbridge: Now well underway and on track to generate approximately $15 million in annualized savings starting in FY, 'twenty, six and being fully realized in FY 'twenty seven.

Stephen A. Trowbridge: Looking at the combined divestitures to spectrum and Merit. This year, we received approximately two times sales for the combined assets and we were able to pay down all of our outstanding debt and strengthen our balance sheet significantly.

Stephen A. Trowbridge: Finally, Steve will discuss in more detail, we reached a settlement with the more than a decade of IP litigation with BD Bard.

Stephen A. Trowbridge: Providing us with clarity and certainty.

Stephen A. Trowbridge: Allowing us to focus on our strategic transformation.

Stephen A. Trowbridge: Mechanical thrombectomy revenue, which includes angiovac and alphavec sales, declined 11.6% over the third quarter of FY23. Angiovac revenue was $5.5 million in the quarter, similar to prior year sales. We are pleased to see this stabilization in angiovac revenue during the quarter. AlphaVac revenue for the third quarter was $1.1 million. As Jim mentioned, we are very pleased to announce the clearance of an expanded indication for Alphabet to treat pulmonary embolism.

Stephen A. Trowbridge: With that I'll turn the call over to Steve Trowbridge, Our executive Vice President and Chief Financial Officer to review the quarter in more detail.

Stephen A. Trowbridge: Thanks, Jim.

Stephen A. Trowbridge: Morning, everybody.

Stephen A. Trowbridge: Before I begin I'd like to direct everyone to the presentation on our Investor Relations website summarizing the key items from our quarterly results as Jim mentioned, unless otherwise noted all metrics and growth rates mentioned during todays call are on a pro forma basis and exclude the results of the dialysis and biosurgery businesses that we divested last June.

Stephen A. Trowbridge: We remain confident that mechanical thrombectomy will be a significant contributor to our long-term growth strategy, and we are excited about the planned new product introductions, as well as our clinical initiatives. Nanoknife disposable revenue during the quarter increased 19.8% year-over-year. Capital sales were robust in the quarter, growing 230.9%, and are a strong driver of future disposable sales. Year to date, NanoKnife disclosable sales are up 15.1%, and total NanoKnife sales are up 25.7%. In addition, as a reminder, earlier this year, we announced that enrollment in Preserve is now 100% complete, and as this data starts to be made public over the course of this calendar year, we look forward to sharing it.

Stephen A. Trowbridge: The picking midline products that we divested last month, and the radio frequency and <unk> support catheter products that'd be recently discontinued.

Stephen A. Trowbridge: Our revenue for the third quarter of FY 'twenty, four increased 8% year over year to $66 million driven by growth in both our med Tech and med device platforms med.

Stephen A. Trowbridge: Med Tech revenue was $25 7 million or 12, 6% year over year increase while med device revenue was $40 3 million growing five 2% compared to the third quarter of FY2023.

Stephen A. Trowbridge: Year to date, our overall revenue is up six 5% year over year with our Med Tech segment up nine 6% and our med device segment up four 6%.

Stephen A. Trowbridge: We were pleased with the return to growth that we saw across both our med Tech and med device businesses in the third quarter, which we had expected and is reflective of the strength of our portfolio.

Stephen A. Trowbridge: In the third quarter, our med device segment grew 5.2% year-over-year, led by strength in our EVLT and angiographic catheter products. Moving down the income statement, our gross margin for the third quarter of FY24 was 51.1 percent, a decrease of 290 basis points compared to the year-ago period. For the third fiscal quarter, MedTech's gross margin was 61.5 percent, a decrease of 300 basis points, and MedDevice's gross margin was 44.4 percent, a decrease of 330 basis points, each one compared to the third quarter of last year. The year-over-year decline in gross margin for the medtech business was primarily driven by product mix, as sales of our higher-margin thrombectomy products declined, and geographic mix as we saw growth in our international market. Gross margin for the med device business was impacted by a supplier recall and costs associated with the transition to outsource manufacturing.

Stephen A. Trowbridge: For the third fiscal quarter on a pro forma basis, our med tech platforms comprised 38, 9% of our total revenue compared to 37, 3% of total revenue a year ago.

Stephen A. Trowbridge: For the nine months ended February 2019, 'twenty 'twenty four our Med Tech segment comprised 38, 4% of our total revenue base versus 37, 3% as of one year ago.

Stephen A. Trowbridge: Our Oregon platform contributed $11 8 million in revenue during the third quarter growing 14, 7% compared to last year.

Stephen A. Trowbridge: Year to date are already on platform is up 17, 4% year over year.

Stephen A. Trowbridge: Mechanical thrombectomy revenue, which includes the angio back end Alphatec sales declined 11, 6% over the third quarter FY2023.

Stephen A. Trowbridge: Year-to-date gross margins for FY24 were 53.6%, a decrease of 150 PPS vs. prior year, with MedTech gross margin of 63% and MedDevice gross margin of 47.7%. As a reminder, the gross margin numbers that I'm referring to for this year, as well as last year, are proforma numbers following the divestiture of our PICs and midline businesses. We did see significant margin expansion when compared to our pre-divestiture margin. However, as we discussed last quarter, our gross margin profile has been negatively impacted by the scale and structural limitations of our operating footprint. To address this, we announce that we are restructuring our manufacturing operations to move to a fully outsourced model. Again, we expect this restructuring to result in annualized savings of roughly $15 million, with the full annualized impact being realized in FY27. Until we can complete this transition,

Stephen A. Trowbridge: <unk> revenue was $5 5 million in the quarter similar to prior year sales. We were pleased to see the stabilization in angio back revenue during the quarter.

Stephen A. Trowbridge: Also that revenue for the third quarter was $1 1 million.

Stephen A. Trowbridge: As Jim mentioned, we are very pleased to announce the clearance of an expanded indication for alphabet to treat pulmonary embolism.

Stephen A. Trowbridge: We remain confident that mechanical thrombectomy, it will be a significant contributor to our long term growth strategy and we're excited about the planned new product introductions as well as our clinical initiatives.

Stephen A. Trowbridge: You had a nice disposable revenue during the quarter increased 19, 8% year over year.

Stephen A. Trowbridge: Capital sales were robust in the quarter growing 239% and are a strong driver of future disposable sales.

Stephen A. Trowbridge: Year to date nano knife disposable sales are up 15, 1% of total net sales are up 25, 7%.

Stephen A. Trowbridge: In addition, as a reminder, earlier this year, we announced that enrollment and preserve its not 100% complete and is this data starts to be made public over the course of this calendar year, we look forward to sharing it with you.

Stephen A. Trowbridge: We will see some.

Stephen A. Trowbridge: We see some ebbs and flows in our reported gross margin. For example, our transition involves moving manufacturing to third-party partners. The faster we do this, the quicker we end up double paying for manufacturing overhead and, therefore, increasing the impact of underabsorption in our Queensberry manufacturing.

Stephen A. Trowbridge: In the third quarter amid device segment grew five 2% year over year led by strength in our E. L T and the angiographic catheter products.

Stephen A. Trowbridge: Moving down the income statement, our gross margin for the third quarter of FY 'twenty four was 51, 1% a decrease of 290 basis points compared to the year ago period.

Stephen A. Trowbridge: It is the right thing to do in connection with our plan, but we cannot fully recognize the impact of our overhead savings until the full transition is complete. In addition, we anticipate building inventory to facilitate the outsourcing move. While there will be continued noise in our gross margins, we're committed to our strategy to ultimately drive efficiencies in our operating footprint and maximize the gross margin expansion that results from growing the percentage of our MedTech revenue base. Turning to R&D, our research and development expense during the third quarter of FY24 was $8.1 million, or 12.2% of sales, compared to $6.7 million, or 11% of sales, a year ago. SG&A expense for the third quarter of FY24 was $34.2 million, representing 51.9% of sales, compared to $32.5 million, or 53.3% of sales, a year ago. Our adjusted net loss for the third quarter of FY24 was $6.5 million, or adjusted loss per share of $0.16, compared to an adjusted net loss of $5.4 million, or adjusted loss per share of $0.14, in the third quarter of last year. The year-over-year decline is largely attributable to lower gross margin and noise associated with the ongoing manufacturing transition.

For the third fiscal quarter Med Tech gross margin was 61, 5% a decrease of 300 basis points and med device gross margin was 44, 4% a decrease of 330 basis points, each when compared to the third quarter of last year.

Stephen A. Trowbridge: The year over year decline in gross margin for the Med Tech business was primarily driven by product mix as sales of our higher margin thrombectomy products declined and geographic mix as we saw growth in our international markets.

Stephen A. Trowbridge: Gross margin for the med device business was impacted by a supplier recall.

Costs associated with the transition to outsource manufacturing.

Stephen A. Trowbridge: Year to date gross margins for FY 'twenty four was 53, 6% a decrease of 150 basis points versus prior year with Med Tech gross margin of 63% and med device gross margin of 47, 7%.

Stephen A. Trowbridge: As a reminder, the gross margin numbers that I'm, referring to for this year as well as last year.

Stephen A. Trowbridge: Our pro forma numbers following the divestiture of our picks and deadline businesses. We did see significant margin expansion when comparing this to our pre divestiture margins.

Stephen A. Trowbridge: As we discussed last quarter, our gross margin profile has been negatively impacted by the scale and structural limitations of our operating footprint.

Stephen A. Trowbridge: To address this we announced that we are restructuring our manufacturing operations to move to a fully outsourced model.

Stephen A. Trowbridge: On a GAAP basis, we recorded a GAAP net loss of $190.4 million, or a loss per share of $4.73, in the third quarter of fiscal 24. The GAAP net loss includes a goodwill impairment charge of $159.5 million, settlement charges, which I will discuss in further detail in a moment, of $22 million, and asset impairment charges totaling $6.8 million related to the transition to outsource manufacturing and discontinuation of Sin Now the goodwill impairment amount is preliminary; it's undergoing further evaluation, and it will be adjusted if necessary prior to filing our quarterly report on Form 10-Q.

We expect this restructuring to result in annualized savings of roughly $15 million with the full annualized impact being realized in FY 'twenty seven.

Stephen A. Trowbridge: Until we can complete this transaction positions, we will see some ebbs and flows in our reported gross margins for.

Stephen A. Trowbridge: For example, our transition incorporates moving manufacturing to third party partners.

Stephen A. Trowbridge: After we do this quicker we ended up double paying for manufacturing overhead and therefore, increasing the impact of under absorption in our Queensbury manufacturing plant.

Stephen A. Trowbridge: Thing to do in connection with our plan, but we cannot fully recognize the impact of our overhead savings until the full transition is complete.

Stephen A. Trowbridge: In addition, we anticipate building inventory to facilitate the outsourcing moves.

Stephen A. Trowbridge: There will be continued noise in our gross margins, we're committed to our strategy to ultimately drive efficiencies in our operating footprint and maximize the gross margin expansion that results from growing the percentage of our med Tech revenue base.

Stephen A. Trowbridge: Adjusted EBITDA in the third quarter of FY24 was negative $3.6 million, compared to adjusted EBITDA of negative $1.5 million in the third quarter of 2023. On February 29, 2024, we had $78.5 million in cash and cash equivalents compared to $44.6 million in cash and cash equivalents at May 31, 2023. As a reminder, we currently have zero debt compared to $50 million a year ago. In the third quarter of fiscal 24, we used $12.5 million in operating cash and capital expenditures of $0.6 million, in addition to ARION placement and evaluation units of $1.2 million. Similar to our discussion around gross margins, we expect that there will be ebbs and flows in our quarterly cash utilization as a result of our manufacturing transfer. Our third fiscal four quarter was particularly noisy with the divestiture of PICS and midlines, the supplier recall I mentioned earlier, and the impact of initiating our strategic manufacturing transfer.

Stephen A. Trowbridge: Turning to R&D, our research and development expense during the third quarter of FY 'twenty four was $8 1 million or 12, 2% of sales compared to $6 7 million or 11% of sales a year ago.

Stephen A. Trowbridge: SG&A expense for the third quarter of FY 'twenty, four was $34 2 million, representing 51, 9% of sales.

Stephen A. Trowbridge: Third to $32 5 million or 53, 3% of sales a year ago.

Our adjusted net loss for the third quarter of FY, 'twenty, four with $6 5 million or adjusted loss per share of <unk> 16.

Stephen A. Trowbridge: Compared to an adjusted net loss of $5 4 million or adjusted loss per share of 14 cents in the third quarter of last year.

Stephen A. Trowbridge: The year over year decline is largely attributable to the lower gross margin and noise associated with the ongoing manufacturing transfer.

Stephen A. Trowbridge: On a GAAP basis, we recorded a GAAP net loss of $190 4 million or a loss per share of $4 73 in the third quarter of fiscal 'twenty for the GAAP net loss includes a goodwill impairment charge of $159 5 million settlement charges, which I will discuss in further detail in a moment of 22 million in asset impairment.

Stephen A. Trowbridge: While we expect continued ebbs and flows in cash, for example, as is always the case, we expect our Q1 to exhibit higher use of cash than other quarters, we are confident that our capital allocation strategy has put us in a strong position. We have a very strong balance sheet with zero debt and a significant cash position, allowing us the flexibility to fund the investments necessary to drive growth in our medtech segment and execute on our strategic manufacturing transit. We went from having $50 million in debt to zero debt in the midst of this high-interest rate environment.

Stephen A. Trowbridge: Charges totaling $6 8 million related to the transition to outsource manufacturing and discontinuation of <unk>.

Stephen A. Trowbridge: Now the goodwill impairment amount is preliminary it's undergoing further evaluation and it will be adjusted if necessary prior to filing our quarterly report on Form 10-Q.

Stephen A. Trowbridge: Adjusted EBITDA in the third quarter of FY 'twenty four it was negative $3 6 million compared to adjusted EBITDA of negative $1 5 million in the third quarter of 'twenty three.

Stephen A. Trowbridge: And in connection with that, we've undergone a significant portfolio optimization, recapitalized our balance sheet, and now have a significant cash position. There will be ebbs and flows to our use of cash as we work to complete our manufacturing transfer over the next 18 to 24 months, but we will continue to remain focused on maintaining a strong balance. Earlier this week, we announced that we entered into a settlement agreement with Becton Dickinson and agreed to settle all outstanding intellectual property litigation with BARD. This has been an overhang in our company for more than 10 years, and although we felt very confident in our position, there's always uncertainty in litigation, and we are very pleased to come to this settlement and avoid the significant cost of further litigation.

Stephen A. Trowbridge: At February 29, 2024, we had $78 5 million in cash and cash equivalents compared to $44 6 million in cash and cash equivalents at May 31, 2023. As a reminder, we currently have zero debt compared to $50 million a year ago.

Stephen A. Trowbridge: In the third quarter of fiscal 'twenty, four we used $12 5 million in operating cash had capital expenditures of <unk> 6 million and additions to our yarn placement and evaluation units of $1 2 million.

Stephen A. Trowbridge: Similar to our discussion around gross margins, we expect that there will be ebbs and flows in our quarterly cash utilization as a result of our manufacturing transfer.

Stephen A. Trowbridge: Third fiscal fourth quarter was particularly noisy with the divestiture of picks and Midlands. The supplier recall I mentioned earlier and the impact of initiating our strategic manufacturing transfer.

Stephen A. Trowbridge: This settlement also provides clarity and certainty, allowing us to remain focused on growing and transforming our business. We will essentially be paying out the equivalent of what was a two-year run rate of legal fees in this matter, but now over the next six years, while also removing the unlikely but still possible threat of a much larger judgment that might have been made against us. Turning now to Guidance.

Stephen A. Trowbridge: While we expect continued ebbs and flows in cash for example, as is always the case, we expect our Q1 two exhibit higher use of cash than other quarters. We are confident that our capital allocation strategy has put us in a strong position.

Stephen A. Trowbridge: Have a very strong balance sheet with zero debt and a significant cash position, allowing us the flexibility to fund investments necessary to drive growth in our med Tech segment and execute on our strategic manufacturing transfer.

Stephen A. Trowbridge: We now anticipate that FY24 revenue will be in the range of $270 to $275 million. The only change in our guidance relative to last quarter is that it contemplates the recent divestiture of the PIC and Midline businesses and discontinuation of the radio frequency ablation and Syntrax. These businesses counted for approximately $50 million of our prior revenue guidance of $320 million to $325 million. We now expect full year adjusted loss per share to be in the range of $0.54 to $0.58. We expect FY24 gross margin to be in the range of 52 to 54 percent, above our prior estimate of 49 to 51 percent, as the divested and discontinued businesses have a lower gross margin relative to our overall corporate revenue.

We went from having $50 million of debt to zero debt in the midst of this high interest rate environment.

Stephen A. Trowbridge: Connection with that we've undergone a significant portfolio optimization recapitalize, our balance sheet and now have a significant cash position.

Stephen A. Trowbridge: There will be ebbs and flows to our uses of cash as we work to complete our manufacturing transfer over the next 18 to 24 months, but we will continue to remain focused on maintaining a strong balance sheet.

Stephen A. Trowbridge: Earlier this week, we announced that we entered into a settlement agreement with Becton Dickinson and agreed to settle all outstanding intellectual property litigation with Bard.

Stephen A. Trowbridge: This has been an overhang on our company for more than 10 years, Although we felt very confident in our position there's always uncertainty in litigation.

Stephen A. Trowbridge: Very pleased to come to this settlement and avoid the significant costs of further litigation.

Stephen A. Trowbridge: The settlement also provides clarity and certainty, allowing us to remain focused on growing and transforming our business.

Stephen A. Trowbridge: For FY24, we continue to expect med tech revenue growth in the range of 10-15%, and we now expect med device revenue growth in the range of 2-4%. We expect MedTech gross margins in the range of 61% to 63%, which is unchanged, and MedDevice gross margins in the range of 46% to 48%, up from our prior guidance of 43% to 45%. And finally, I would like to thank our team here at AngioDynamics for their hard work and commitment in making our transformation possible. With that, I'll turn it back to Jim.

Stephen A. Trowbridge: We will essentially be paying out the equivalent of what was a two year run rate worth of legal fees in this matter, but now over the next six years, while also removing the unlikely but still possible threat of a much larger judgment that might've been made against us in the future.

None: Turning now to guidance.

None: We now anticipate that FY 'twenty four revenue will be in the range of 270 to 275 million.

None: The only change in our guidance relative to last quarter is that a contemplates. The recent divestiture of the <unk> deadline businesses and discontinuance of the radio frequency ablation and <unk> businesses.

None: These businesses accounted for approximately $50 million of our prior revenue guidance of $3 20 to $3 25.

James C. Clemmer: Thanks, Steve. And thanks for joining us on our call today. We acknowledge that there are a lot of moving pieces this quarter between the divestiture and the discontinued products, the BART settlement, and the manufacturing transition. With that said, all of this is in service of executing against the strategy that we laid out back in July of 2021 and moves us closer to being a high-growth med-tech company. The approval of our AlphaVac PE that we announced today is another great example of our strategic focus on adding indications in large, high-growth markets, moving ahead as we are able to leverage these significant changes. The benefits of our transformation will become more and more apparent. Operator, we can open up the line for calls.

None: We now expect full year adjusted loss per share to be in the range of 54 to 58 cents.

None: We expect FY 'twenty four gross margin to be in the range of 52% to 54% above our prior estimate of 49% to 51% as the divested and discontinued businesses have a lower gross margin relative to our overall corporate margins.

None: For FY 'twenty four we continued to expect med tech revenue growth in the range of 10% to 15% and we now expect med device revenue growth in the range of 2% to 4%.

None: We expect med tech gross margins in the range of 61% to 63%, which is unchanged and med device gross margins in the range of 46% to 48% up from our prior guidance of 43% to 45%.

And finally I would like to thank our team here at Angio dynamics for their hard work and commitment in making our transformation possible.

Operator: Thank you. At this time, we'll be conducting a question and answer session. If you'd like to ask a question, please press star 1 on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may remove your question from the queue by pressing star 2. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the start button.

None: With that I'll turn it back to Jim.

James C. Clemmer: Yeah, Thanks, Steve and thanks for joining us on our call today, we acknowledge that there are a lot of moving pieces this quarter between the divestiture and the discontinued products the Bart settlement and the manufacturing transition.

James C. Clemmer: With that said all of this in service of executing against the strategy that we laid out back in July of 2021, and moves us closer to being a high growth Med Tech company.

Operator: One moment, please, while we poll for questions. Thank you. Our first question comes from the line of Jayson Bedford with Raymond James. Please proceed with your question.

None: The approval of our Alpha Vac P E that we announced today is another great example of our strategic focus on adding indications and large high growth markets.

Jayson Tyler Bedford: Good morning. Can you hear me okay?

James C. Clemmer: Hi Jayson. Good morning. Yes.

Jayson Tyler Bedford: Okay, maybe just a few here. So you piqued my interest with your comments about the results of the APEX trial. When will we see data from that trial?

None: Moving ahead as we are able to leverage these significant changes the benefits of our transformation will become more and more apparent.

None: Operator, we can open up the line for calls.

Stephen A. Trowbridge: We've got some trade shows that are coming up soon, Jayson. One, I think, believe this month, another one in a couple months, so it's the Sky as well as PERT.

None: Thank you at this time, we'll be conducting a question and answer session. If you'd like to ask a question. Please press star one on your telephone keypad, a confirmation tone will indicate your line is in the question queue.

Stephen A. Trowbridge: We do expect you're gonna start seeing a pretty good release, both the publications as well as podium presentations from our principal investigators that were part of the APEX trial. As Jim mentioned, we're excited for that data to get out there. The results of the trial even exceeded our expectations. We knew we had a good product, but we were very pleased with what we saw, both in terms of hitting the primary endpoints and especially what Jim talked about around overall clot removal. We think it's gonna be a nice differentiator for us.

None: You may remove your question from the queue by pressing star two.

None: For participants using speaker equipment, it may be necessary to pick up your handset before pressing pressing the star keys.

None: One moment, please while we poll for questions.

None: Thank you. Our first question comes from the line of Jayson Bedford with Raymond James. Please proceed with your question.

None: Okay.

Jayson Tyler Bedford: Hi, Good morning can you hear me, Okay Hi.

Jayson Tyler Bedford: Hi, Jason Good morning, Yes.

Jayson Tyler Bedford: Okay, maybe just a few here so you piqued my interest with your comments around the results of the apex trial.

Jayson Tyler Bedford: Okay, and can you just remind us of the timing of enhancements to AlphaVac?

James C. Clemmer: So Jayson, in the second half of this calendar year, you'll see a couple of new products being launched, and a couple of new R&D design element changes that we added based on feedback we received during the study. So we look forward to the second half of the year. At this point, we're not going to comment on specific details, but you'll see that in the second half of this calendar year.

Jayson Tyler Bedford: When do we see data from that trial.

Jayson Tyler Bedford: You've got some trade shows that are coming up soon Jason one that I think believe this month. Another one in a couple of months. So that's the sky as well as as part we.

Jayson Tyler Bedford: We do expect Youre going to start seeing a pretty good release, both the publications as well as podium presentations from our principal investigators that were part of the apex trial as Jim mentioned, we're excited for that data to get out there with the.

Jayson Tyler Bedford: The results of the trial they exceeded even our expectations. We knew we had a good product, but we were very pleased with what we saw both in terms of hitting the primary endpoints and especially what Jim talked about around overall clot removal, we think it's gonna be a nice differentiator for us.

James C. Clemmer: And those are contingent on, it's a 510K? Yeah, there's regulatory clearance involved, right? There are.

Stephen A. Trowbridge: We have a couple things coming out. I think one might be a letter to file, and one's a 510-K, but it just depends on which design elements we're gonna have.

None: Okay and can you just remind us on the timing of of enhancements to alphabet.

None: Sure Jason in the second half of this calendar year, you'll see a couple of new products being launched a couple of new R&D design element changes that we added based on feedback we received during the study. So we look forward to the second half of the year at this point, we're not going to comment on specific details, but you'll see that in the second half of the calendar year.

Jayson Tyler Bedford: I appreciate that there's obviously a lot of moving pieces here. I appreciate that you're not changing guidance outside of the divestiture, but the guidance seems to imply a little slower growth in the fiscal fourth quarter. Are you seeing anything relative to the third quarter specifically? Is there anything that you're seeing specifically in the business, or is this just more a function of not wanting to make it noisier by keeping the guidance out?

None: And those are contingent on it it's a five 10-K, yes, there's regulatory clearance involved right.

James C. Clemmer: Jason, we're not seeing anything in the market that has shifted or changed, you know the blend of headwinds and tailwinds and we've talked about some of those, but no we haven't seen any market forces nor we changed really the guidance we gave, we really just wanted to keep it consistent with all the moving parts we have going on right now, we thought it was simple to keep it consistent, we're comfortable with that range and I think for our investors it shows a simple stable change.

None: There are we have a couple of things coming out of I think one might be a letter to file one to 500 10-K, but just depending on which design elements, we're going to add.

None: Yeah.

None: Okay.

None: I appreciate the just on theirs.

None: We spent a lot of moving pieces here I appreciate that you're not changing guidance outside of the divestiture, but the guidance seems to imply a little slower growth in the fiscal fourth quarter.

None: Are you seeing anything relative to the.

None: The third quarter, specifically is there anything that youre seeing specifically in the business or is this just more a function of.

Jayson Tyler Bedford: And as you said, there's disruption going on in terms of the best in the products, making some of the changes that we made in the sales force, and dealing with the manufacturing transfer. There's a lot going on, but we're confident we can manage through that and maintain the guidance level that we had set out.

None: Not wanting to make it no easier by keeping the guidance as is.

None: Yeah, Jason we were not seeing anything in the market that has shifted or changed there's obviously a good blend of headwind and tailwind that we've talked about some of those but but no. We haven't seen any market forces nor are we change really in the guidance. We gave we really just wanted to keep it consistent with all the moving parts, we have going on right now we thought it was simple to keep it consistent we're comfortable with that range and think for investors of shows a simple stable.

Steven Michael Lichtman: Maybe just last one for me. You kind of alluded to capital deployment plans. You've got a lot of cash. I realize there's a need to fund the business, but any thought of either kind of buyback or just being a little bit more active with the cash?

Steven Michael Lichtman: So two points, active with the cash. I think we've signaled Jayson.

None: Change and as you said, there's there's disruption going on in terms of divesting the products, making some of the changes that we've made in the sales force dealing with the manufacturing transfer Theres a lot going on but we're confident we can manage through that and maintain the guidance level that we had set out.

James C. Clemmer: We really love the portfolio we have today in the medtech side. Three great platforms. They're not just products. They're really platforms that you'll see more opportunities spin off in the coming years. So we're not looking to maybe acquire anyone else's product or asset to add to our base. And second, as far as a buyback, those are things we'll discuss at the board level and communicate maybe in the future.

None: Yeah.

None: Okay maybe.

None: Maybe just last one for me.

None: You've kind of alluded to capital deployment plans.

None: You've got a lot of cash I realize there's a need to fund the business, but any thought of either kind of buyback or just being a little bit more active with the cash.

Jayson Tyler Bedford: Okay, thank you.

Steven Michael Lichtman: Thank you. Our next question comes from the line of Steve Lichtman with Oppenheimer & Company. Please proceed with your question.

None: So two points acted with the cash I think we've signaled Jason we really love the portfolio. We have today in the med Tech side three great platforms, they're not just product, they're really platforms that you'll see more opportunities spin off in the coming years. So we're not looking to maybe acquire anyone else's product or asset to add to our base.

Steven Michael Lichtman: Thank you. Good morning, Jim and Steve.

James C. Clemmer: I guess first, can you talk about the rollout plans for AlphaVac in PE? What kind of training effort will be needed? And will you look to add to the commercial team so as not to impact AngioVac? Just wondering how you're thinking about that.

None: Secondly, as far as our buyback those are things, we'll discuss at the board level and communicate maybe in the future.

None: Yeah.

None: Okay. Thank you.

James C. Clemmer: Thanks Steve, good question. So if you go back to nearly a year ago, we added a new head of sales for that group, a really experienced, great sales leader that we brought on. We added some people to our training and education departments. We changed some of our sales management team and our sales team.

None: Yeah.

None: Thank you. Our next question comes from the line of Steve Lichtman with Oppenheimer and company. Please proceed with your question.

Steven Michael Lichtman: Thank you good morning, Jim and Steve.

Steven Michael Lichtman: I guess first can you talk about the rollout plans for core alpha back in P/e, what kind of training effort will be needed.

James C. Clemmer: So we've done a lot of moving parts over the last six to nine months, adapting to what we thought would be necessary changes in the build we wanted to do to get our team ready for this moment. So we're still going through some of the educational changes, some of the validation of our training and education here for our internal team. We're really excited about the level that we raised our bar to because this is such a significant event for us. So Steve, we really have a really disciplined approach to this, and we put a lot of energy and effort, as you know, into the design elements of the product. And then there was the APEX study itself, which was really well done.

Steven Michael Lichtman: You look to add to the commercial team so as not to impact and go back just wondering how youre thinking about that.

None: Thanks, Steve Good question. So if you go back to nearly a year ago, we added a new head of sales for that group really experienced great sales leader that we brought on we added some people to our training and education departments.

None: Changed some of our sales management team and our sales team. So we've done a lot of moving parts over the last six to nine months adapting to what we thought would be necessary changes in the build we wanted to do to get our team ready for this moment. So we're still going through some of the educational changes some of the validation of our training and education here for our internal team we're really excited.

James C. Clemmer: We had some great PIs and some sites that generated good data for us. But we're putting the same level of discipline into our preparation for our launch. So you'll see, as we mentioned on the call today, we've only got about two months left in our fiscal 2024. We have a limited market release. That will do now. So it will be controlled so our reps are well trained and ready to support our customers. And then, looking for the summer launch of FY25, we'll be ready to go on a larger basis.

None: At about the level that we raised our bar too because this is such a significant event for us. So Steve we really havent really disciplined approach towards this but a lot of energy and effort as you know the design elements of the product and then the apex study itself, which was really well done we had some great. P is it's a site that generated good data for us where we're putting the same level of discipline.

None: Our preparation for our launch so you'll see as we mentioned on the call today, we've only got about two months left in our fiscal 2024, we have a limited market release that will do now so it will be controlled so our reps are well trained and ready to support our customers and they are looking for the summer launch of our FY 'twenty five we'll be ready to go on a larger basis.

Steven Michael Lichtman: Thanks, Jim. Steve, you mentioned gross margin, you know, some ebbs and flows. Just in terms of an early look at FY25, I mean, directionally, do you anticipate gross margin on a pro forma basis being up, or any color that you can provide?

None: Thanks, Ken and Steve you mentioned.

None: On gross margin.

Stephen A. Trowbridge: Yeah, so we'll typically give detailed margin guidance for 25% when we get to our Q4 results. That's typically our cadence, and we'll stick to that.

None: So some ebbs and flows.

None: Just in terms of an early look at FY 'twenty five any directionally do you anticipate gross margin on a pro forma basis being up or any any color that you can provide.

Stephen A. Trowbridge: I think the high-level trends that you're going to see is that we do expect the step-up that we saw with the divestiture, and that's going to continue. But as I mentioned in our overall manufacturing transfer plan, there's going to be noise and gross margin. We've got a little bit of a balancing act here, where the faster we move products out of our Queensborough manufacturing facility and get them into our third-party manufacturing hands, while we're doing that, we're still double-paying for overhead. So you're going to see some pressure on gross margins until we can fully get through that manufacturing transfer. So it's almost like the faster we get going, the more we see a little bit of a hit. It's the right thing to do for our plans, but it is going to create some of that noise.

None: Yes, so we will typically give detailed margin guide.

None: Guidance for 25, when we get to our Q4 results Thats typically our cadence and we'll stick to that I think the high level.

I know that Youre going to see is we do expect to step up that we saw with the divestiture and that's going to continue but as I mentioned in our in our overall manufacturing transfer plan, there's going to be noise in gross margin, you've got a little bit of the.

Kind of balancing act here, where the faster we move products out of our Queensbury manufacturing facility and get them into our third party manufacturing hands, while we're doing that we're still double pay for overheads youre going to see some pressure on gross margins until we can fully get through that manufacturing transfer. So it's almost like a faster we get going the more we see a little bit of a hit it's the right thing to do for our <unk>.

Stephen A. Trowbridge: We'll give you a little bit more detail as we get into 24, but look, overall, margin, we believe, is one of the areas that we absolutely have to address to really see that continued gross margin accretion that you get from the larger portion of our overall revenue base coming from MedTech. We've seen that, but it's been eaten up by some of the structural limitations that we've talked about over the last couple of quarters. So once we get through this transition, you're really going to see that margin profile take off. It's going to be noisy as we go through it.

None: Lands, but it is going to create some of that noise will give you a little more detail as we get into 'twenty four but look at overall margin. We believe is one of the areas that we absolutely have to address to really see that continued gross margin accretion that you get from the from the larger portion of our overall revenue base coming from Med Tech, we've seen that but it's been eaten up by some.

None: Some of the structural limitations that we've talked about over the last couple of quarters. So once we get through this transition you're really going to see that margin profile takeoff, it's gonna be noisy as we go through it.

Steven Michael Lichtman: And just lastly, just on cash, you know, obviously you're clear in terms of the gross margin impact of the most recently divested products. But were they sort of cash accretive, though? Any thoughts on how we should be thinking about, you know, what kind of cash that those businesses threw off?

None: Got it and then just lastly, just on cash obviously, you're clear in terms of the gross margin impact of the most recently divested products, where they use of cash accretive, though just any any how should we be thinking about what kind of cash that those businesses through off that may not be in place.

Stephen A. Trowbridge: Now, they were cash accretive, and we talked about that before, so there are a couple things going on. If you remember when we did the divestiture of the dialysis and biocentry products at the very beginning of this fiscal year, we had said that that was going to be a little bit more dilutive to EPS and certainly more dilutive to cash because there weren't any direct costs that went out when we did that divestiture, but it was the right thing to do for us opportunistically. We timed it. It led to us getting a combined multiple for all the assets that we sold during the two times. These assets did allow us to take some direct costs out, and so we talked about some assets that went with our pick and midline business as well as the restructuring that we did, so we're able to mitigate that. There's no doubt, though, as we said, these products didn't take a lot of investment. There was some cash generation that was provided to us in the overall company that we'll be working through as we create the overall structure of the company heading into 25 and beyond.

None: Or are they not thanks.

None: No they were cash accretive and we talked about that before so there's it there's a couple of things going on if you remember when we did the divestiture of the dialysis and biosurgery products in the very beginning of this fiscal year.

None: Said that that was going to be a little bit more dilutive to EPS and certainly more dilutive to cash because there weren't any direct costs that went out when we did that divestiture, but it was the right thing to do for us Opportunistically, we timed it led to us getting a combined multiple for all of the assets that we sold into the into the two times. These assets did allow us to take some direct costs out and so we talked about some.

None: The assets that went with our picking midline business as well as the restructuring that we did so we're gonna we're able to mitigate that.

None: Theres no doubt, though as we said these products they didn't take a lot of investment there was some cash generation that provided to us in the overall company that we'll be working through as we go as we create the overall structure of the company heading into 'twenty five and beyond.

Steven Michael Lichtman: Okay, I got it. Thank you, guys.

None: Okay got it thank you guys.

Operator: Thanks, people.

None: Thanks, Steve.

John Edward Young: Thank you. As a reminder, if you'd like to join the question queue, please press star 1 on your telephone keypad. Our next question comes from the line of John Young with Canaccord Genuity. Please proceed with your question.

Thank you as a reminder, if you'd like to join the question queue. Please press star one on your telephone keypad. Our next question comes from the line of John Young with Canaccord Genuity. Please proceed with your question.

John Edward Young: Good morning, Jim and Steve. Thanks for taking our questions. Maybe just to turn back to the AlphaVac with a new indication, and can you talk about what the commercial sales force size is today, how many sensors you're in, and just, you know, the approach going forward? Do you think you need more registries and studies given just the high level of data that's being generated in this sector? And lastly, just on the pricing strategy. Thanks.

John Edward Young: Hi, Good morning, gentlemen, thanks for taking my questions, maybe just to turn back to be alpha back within your indication.

John Edward Young: Can you talk about what the commercial sales force size is today, how many centers here and just.

John Edward Young: The approach going forward do you think you need more registration studies.

John Edward Young: The high level of data that's being generated in the sector and lastly, just on pricing strategy. Thanks.

James C. Clemmer: Hi John, thanks for the questions. We'll try to make sure I remember them. Stephen, I'll cover them for you. So today, a couple things.

None: Hi, John Thanks for the questions, we'll try to make sure I remember Stephen I'll cover them for you.

James C. Clemmer: We've, you know, 40 sales reps, we've talked about it before, in this business, dedicated to AlphaVac and AngioVac. As I said in the last question, they're now being, you know, well-trained, and are, you know, prepared for the launch. So we really had, you know, a little over 20 sites in our APEX trial. And not all of our reps actually serviced each of those sites. So the ones that did, we think, are really well-versed and ready to go, and other ones are being properly trained and ready to launch. So a couple things like that are happening as we speak. But we like the sales force we have; we like where they're located, how they've been trained, and their quality of what they know and their knowledge of the space. We also have a plan to add more as we grow. But today, we're gonna start with the 40 reps we have today. I'm also,

None: So today a couple of things.

Stephen: We've got 40 sales reps, we've talked about it before I missed business dedicated to alpha vacuum <unk> as I said on the last question you know that they're now being you know the well trained being prepared for the launch. So we really had you know a little over 20 sites in our apex trial, so not all of our reps actually service each of the sites. So the ones that did we think a really well versed and ready to go.

Stephen: Other ones are being properly trained and ready to launch so a couple of things like that are happening as we speak but we'd like the sales force. We have we like where they're located how they have been trained and they're quality of what they know when the knowledge of the space. We also have a plan to add as we grow but today, we are going to start with a 40 reps we have today.

Stephen: Our muscle.

Stephen A. Trowbridge: So there's a question about the clinical data. We're excited to get the APEX results out. We think that those APEX results are gonna be meaningful. We're also excited to get the CE mark that Jim talked about and launch it in international markets. I would expect that you're gonna see some continued data generation efforts for us around thrombectomy. As we know, this is a very exciting space. It's growing. You've also got a number of very well-established competitors that we're going up against. We think our product has some real advantages, and so yeah, we're gonna support that with continued data generation efforts. That could be in the form of some registries. It could be in the form of some investigator-initiated trials, but I would expect that you'll see us continue to build that foundation over the coming years.

Stephen: So it was a question about the clinical and clinical data.

Stephen: We're excited to get the apex results out we think that those apex results are going to be meaningful.

We're also excited to get the CE, Mark that Jim talked about and watch it in international markets I would expect that youre going to see some continued data generation.

Stephen: It's for us around thrombectomy as we know this is this is a very exciting space. It's growing you've also got a number of very well situated competitors that we're going up against we think our product has some real advantages and so yeah, we're going to support that with continued data generation efforts that could be in the form of some registry as it could be in the form of some investigator initiated trials.

Stephen: But I would expect that Youll see us to continue to build our foundation over the coming years.

James C. Clemmer: And finally, as far as pricing is concerned, John, we have a unique device. Call it about the $9,000 range, which is what you'd expect for Alphabet.

Stephen: And finally as far as pricing John we have a unique device.

None: Call. It about the $9000 range is what you would expect Ralph back.

John Edward Young: Great, thank you so much for answering. I was going to throw a lot at you. And just, you know, turning to Nionize too and the strong quarter you had around there, can you talk about, you know, what's clicking there? When can we see the initial preservation data this year? And is there any way to characterize how much of the probe sales were for prostate cancer? Thanks so much again for taking the questions.

Great. Thank you so transfer I was out there a lot of that year and just trying to know.

None: The strong quarter you had around there can you just about whats clicking there when can we see the initial data this year and is there any way to characterize how much of the probe sales were her thanks.

Thanks, So much again for taking the question.

Stephen A. Trowbridge: Yeah, really good question. So we are excited about some of the strong capital sales that we've seen. As we've said, capital can be choppy. That's why we started a couple years ago making sure that we were focusing on probe growth, because that's a nice proxy for what you're seeing in terms of procedure growth for NanoKnife. So we're seeing both good things.

None: Yes really good question. So we are excited about some of the strong capital sales that we've seen as we've said capital can be choppy and that's why we started a couple of years ago, making sure that we were focusing on pro growth because that's a nice that's a no.

None: Nice proxy for what Youre seeing in terms of procedure growth for nano life. So we're seeing both good things, we're seeing 20 plus percent growth in probes thats pretty been pretty consistent as well as some of the nice growth that we saw in capital capital is going to be a harbinger for future probe sales.

Stephen A. Trowbridge: We're seeing good 20 plus percent growth in probes. That's pretty consistent, as well as some of the nice growth that we saw in capital. Capital is going to be a harbinger for future probe sales. With respect to when we're gonna see some data out of Preserve, as we said, we completed enrollment last July. We're gonna finish the 12-month follow-up this summer.

None: With respect to when we're going to see some data out of preserve as we said we completed the enrollment last July we finished at 12 months follow up this summer coming out of that Youre going to be very similar to what we talked about with alpha that you'll start seeing publications, you'll start seeing some podium presence from our principal investigators there kind.

Stephen A. Trowbridge: Coming out of that, you're gonna, very similar to what we talked about with AlphaVac, start seeing publications, you'll start seeing some podium presence from our principal investigators there, kind of coming on the heels of the submission, as well as the expected approval that we are looking for for NanoKnife for Prostate. On the probe growth, Prostate is a big driver of that. There's no doubt about that, both here in the United States and in international markets. I think the prostate is probably our highest utilization organ now, and that flips from where it had been, where you're typically in the liver and pancreas. So the prostate initiative that we've embarked on, getting the trial done, what our expectations are going forward, we're really seeing strong momentum coming from urologists picking up this technology and using it to treat prostate cancer.

None: Kind of coming on the heels of the submission as well as the expected approval that would be that we are.

None: Or are looking for for nano nicer prostate on the probe growth prostate is a big driver of that Theres no doubt about that both here in the United States as well as in international markets I think prostate is probably our highest utilization Oregon now.

None: That flipped from where it had been and where you have typically in liver and pancreas. So the prostate initiatives that we've embarked on getting the trial done what our expectations are going forward, we're really seeing strong momentum coming from urologists picking up this technology and using it to treat prostate.

John Edward Young: Great, thank you.

None: Okay.

None: Great.

None: Okay.

James C. Clemmer: Thank you. Ladies and gentlemen, I'm showing no other questions at this time. I'll turn the floor back to Mr. Clemmer for final comments.

James C. Clemmer: Thank you, ladies and gentlemen, I'm showing no other questions at this time I'll turn the floor back to Mr. Clemmer for final comments.

James C. Clemmer: And thank you, and again, thank you guys for joining us today on our call. I really want to reach out to our employees who have worked really, really hard over the last number of years and years, especially the last few quarters, preparing our company for this transformation to a high-tech, high-growth company with unique design elements built into each of our products. Our team has gone through a lot of adversity and powered through it, and now we've delivered excellent clinical results with the AlphaVac as one example of what you think you can come to expect from us in years to come. So a shout out and a thank you to our employees. Talk to you soon.

James C. Clemmer: And thank you and again, thank you guys for joining us today on our call I really want to reach out to our employees have worked really really hard in the last number of years and years, especially the last few quarters preparing our company for this transformation to a high Tech high growth company with unique design elements built into each of our products. Our team has gone through a lot of adversity and power through it and now we've delivered excellent.

James C. Clemmer: Clinical results with the Alpha back as one example of what you think you can come to expect from us in years to come so a shout out and a thank you to our employees and talk to you soon.

Operator: Thank you. This concludes today's conference call. You may disconnect your lines at this time. Thank you for your participation.

None: Thank you. This concludes today's conference call you may disconnect. Your lines at this time. Thank you for your participation.